Molecular glue degraders: Lilly, AbbVie sign billion-dollar deals; BMS leads with three late-stage drugs

Data Compilation
#PharmaFlow

Pipeline Prospector March 2025: Trump’s FDA overhaul spooks biotech stocks; Roche, AbbVie, Novo ink obesity drug deals

Stock Recap
#PipelineProspector

Oxybutynin Chloride

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

23 API Suppliers, 13 USDMF, 10 CEP/COS, 3 JDMF, 2 EU WC, 1 KDMF, 11 NDC API, 9 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

2 Intermediate Suppliers

2 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

94 FDF Dossiers, 61 FDA Orange Book, 12 Europe, 10 Canada, 5 South Africa, 6 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, GEL;TRANSDERMAL - 10% (100MG/PACKET) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 4 Evonik, 2 Rochem International Inc, 20 SPI Pharma, 7 DKSH, 7 Faran Shimi Pharmaceutical, 1 Boai NKY Pharmaceuticals Ltd, 7 Gangwal Healthcare, 7 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 1 Capital Farma, 1 ACG Worldwide, 12 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 30 BASF, 1 Clariant, 14 Corel Pharma Chem, 7 DFE Pharma, 3 Doshion Polyscience, 2 Finar, 12 Gangwal Chemicals, 9 Ideal Cures Pvt Ltd, 5 Ingredion Pharma Solutions, 37 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 16 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nomisma Healthcare, 2 Novo Excipients, 3 Pharmatrans-Sanaq, 8 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 29 Roquette, 14 Seppic, 7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 12 Sigachi Industries, 2 The Dow Chemical Company, 2 Valens Pharmachem, 5 Vasa Pharmachem, 1 Vertellus, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

85 Fillers, Diluents & Binders, 66 Coating Systems & Additives, 41 Controlled & Modified Release, 35 Direct Compression, 31 Disintegrants & Superdisintegrants, 30 Solubilizers, 28 Granulation, 28 Taste Masking, 27 Film Formers & Plasticizers, 27 Thickeners and Stabilizers, 24 Parenteral, 23 Lubricants & Glidants, 18 Topical, 17 Chewable & Orodispersible Aids, 16 Co-Processed Excipients, 9 Emulsifying Agents, 7 Rheology Modifiers, 6 API Stability Enhancers, 5 Empty Capsules, 5 Surfactant & Foaming Agents, 5 Coloring Agents, 4 Vegetarian Capsules, 1 Soft Gelatin

DIGITAL CONTENT

17 News #PharmaBuzz

17 News #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 13 Regulatory FDF Prices

MARKET PLACE

8 APIs

8 APIs

PATENTS & EXCLUSIVITIES

3 US Patents, 8 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 USP, 1 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Holder	DMF No.	Subject	Submission Date	Status	Type	GDUFA DMF Review	GDUFA Review Date	GDUFA Payment Date
28/03/2025	Sanofi	France	SANOFI AVENTIS SPA	12840	OXYBUTYNIN CHLORIDE	1998-02-02	Inactive	II	N/A
28/03/2025	Seqens	France	PCAS	6412	OXYBUTYNIN CHLORIDE USP	1986-06-12	Active	II	Complete	2013-05-09	2013-04-30

Oxybutynin Chloride

Oxybutynin Chloride

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

23 API Suppliers

13 USDMF

10 CEP/COS

3 JDMF

2 EU WC

1 KDMF

11 NDC API

9 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

INTERMEDIATES

2 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

94 FDF Dossiers

61 FDA Orange Book

12 Europe

10 Canada

5 South Africa

6 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

GEL;TRANSDERMAL - 10% (100MG/PACKET) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 EUROAPI

4 Evonik

2 Rochem International Inc

20 SPI Pharma

7 DKSH

7 Faran Shimi Pharmaceutical

1 Boai NKY Pharmaceuticals Ltd

7 Gangwal Healthcare

7 Nanjing Well Pharmaceutical

2 Pfanstiehl

1 Capital Farma

1 ACG Worldwide

12 Actylis

1 Aeon Procare

1 Alcedo Pharmachem

8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

30 BASF

1 Clariant

14 Corel Pharma Chem

7 DFE Pharma

3 Doshion Polyscience

2 Finar

12 Gangwal Chemicals

9 Ideal Cures Pvt Ltd

5 Ingredion Pharma Solutions

37 Kerry

3 Kima Chemical

6 Lonza Capsugel

16 Microlex e.U

1 Nanjing Bold Chemical

2 Nomisma Healthcare

2 Novo Excipients

3 Pharmatrans-Sanaq

8 Pluviaendo

4 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

29 Roquette

14 Seppic

7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

2 Shijiazhuang Huaxu Pharmaceutical

12 Sigachi Industries

2 The Dow Chemical Company

2 Valens Pharmachem

5 Vasa Pharmachem

1 Vertellus

1 Zhejiang Huakang Pharmaceutical

TABLET, EXTENDED RELEASE;ORAL - 10MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - 15MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - 5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GEL;TRANSDERMAL - 10% (100MG/PACKET) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons